BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37500691)

  • 1. microRNA sequencing for biomarker detection in the diagnosis, classification and prognosis of Diffuse Large B Cell Lymphoma.
    Larrabeiti-Etxebarria A; Bilbao-Aldaiturriaga N; Arzuaga-Mendez J; Martin-Arruti M; Cozzuto L; Gaafar A; Ruiz-Diaz I; Guerra I; Martin-Guerrero I; Lopez-Lopez E; Gutierrez-Camino A
    Sci Rep; 2023 Jul; 13(1):12159. PubMed ID: 37500691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.
    Ayoubian H; Ludwig N; Fehlmann T; Menegatti J; Gröger L; Anastasiadou E; Trivedi P; Keller A; Meese E; Grässer FA
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
    Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
    J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review of the Potential of MicroRNAs in Diffuse Large B Cell Lymphoma.
    Larrabeiti-Etxebarria A; Lopez-Santillan M; Santos-Zorrozua B; Lopez-Lopez E; Garcia-Orad A
    Cancers (Basel); 2019 Jan; 11(2):. PubMed ID: 30691158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL).
    Mazan-Mamczarz K; Gartenhaus RB
    Leuk Res; 2013 Nov; 37(11):1420-8. PubMed ID: 24054860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma.
    Cao D; Cao X; Jiang Y; Xu J; Zheng Y; Kang D; Xu C
    Hematol Oncol; 2022 Apr; 40(2):172-180. PubMed ID: 34874565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
    Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
    BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of the molecular mechanisms, shared gene signatures, and MicroRNAs between systemic lupus erythematosus and diffuse large B cell lymphoma by bioinformatics analysis.
    Peng Z; Liang X; Lin X; Lin W; Lin Z; Wei S
    Lupus; 2022 Oct; 31(11):1317-1327. PubMed ID: 35817571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression.
    Sun R; Zheng Z; Wang L; Cheng S; Shi Q; Qu B; Fu D; Leboeuf C; Zhao Y; Ye J; Janin A; Zhao WL
    Mol Oncol; 2021 Jan; 15(1):246-261. PubMed ID: 33107145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients.
    Lim EL; Trinh DL; Scott DW; Chu A; Krzywinski M; Zhao Y; Robertson AG; Mungall AJ; Schein J; Boyle M; Mottok A; Ennishi D; Johnson NA; Steidl C; Connors JM; Morin RD; Gascoyne RD; Marra MA
    Genome Biol; 2015 Jan; 16(1):18. PubMed ID: 25723320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating miRNAs as biomarkers in diffuse large B-cell lymphoma: a systematic review.
    Lopez-Santillan M; Larrabeiti-Etxebarria A; Arzuaga-Mendez J; Lopez-Lopez E; Garcia-Orad A
    Oncotarget; 2018 Apr; 9(32):22850-22861. PubMed ID: 29854319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance.
    Feng Y; Zhong M; Zeng S; Wang L; Liu P; Xiao X; Liu Y
    Epigenomics; 2019 Jan; 11(1):35-51. PubMed ID: 30211623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.
    Li C; Kim SW; Rai D; Bolla AR; Adhvaryu S; Kinney MC; Robetorye RS; Aguiar RC
    Blood; 2009 Jun; 113(26):6681-90. PubMed ID: 19278952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs.
    Paszkiewicz-Kozik E; Paziewska A; Kulecka M; Dąbrowska M; Kluska A; Bałabas A; Piątkowska M; Ambrożkiewicz F; Tajer J; Osiadacz W; Romejko-Jarosińska J; Kotarska M; Żeber-Lubecka N; Karczmarski J; Popławska L; Mikula M; Rutkowski P; Walewski J; Ostrowski J
    Biomed Res Int; 2021; 2021():3212878. PubMed ID: 33628777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients.
    Hu M; Wang X; Liu N; Ding K; Zhang G; Liu X
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34109978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study.
    Shi Y; Ding W; Gu W; Shen Y; Li H; Zheng Z; Zheng X; Liu Y; Ling Y
    J Leukoc Biol; 2022 Dec; 112(6):1633-1648. PubMed ID: 36040107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of the potential of MicroRNAs in the management of patients with follicular lymphoma.
    Arzuaga-Mendez J; Lopez-Santillan M; Garcia-Ruiz JC; Lopez-Lopez E; Martin-Guerrero I
    Crit Rev Oncol Hematol; 2021 Mar; 159():103247. PubMed ID: 33515703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
    Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
    Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
    Troppan K; Wenzl K; Pichler M; Pursche B; Schwarzenbacher D; Feichtinger J; Thallinger GG; Beham-Schmid C; Neumeister P; Deutsch A
    Int J Mol Sci; 2015 Aug; 16(8):18077-95. PubMed ID: 26251897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significance of FOXP1 in diffuse large B-cell lymphoma.
    Gascoyne DM; Banham AH
    Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.